No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 339 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Dabrafenib Plus Trametinib Improves Efficacy in Children and Adolescents with Relapsed/Refractory... September 19, 2023 This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her... November 5, 2019 HBV Infection Associated with Increased Risk of Primary Extrahepatic Malignancies May 23, 2022 Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in... March 11, 2024 Load more HOT NEWS Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy... Today is Random Acts of Kindness Day Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event...
